The HSPA6 Knockout NCI-H1975 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the HSPA6 gene in NCI-H1975 human lung adenocarcinoma cells. This loss-of-function model is generated using CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous polyclonal pool suitable for functional studies without clonal selection. The cells enable assessment of HSPA6 ablation on population-level phenotypes in stress response and cancer biology assays.
The NCI-H1975 host cell line is a human lung adenocarcinoma cell line isolated from a non-small cell lung cancer patient, and it serves as a widely used model for NSCLC research. These epithelial cells harbor endogenous EGFR L858R and T790M mutations, which confer constitutive kinase activity and resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs). Consequently, NCI-H1975 cells are extensively employed to investigate mechanisms of acquired drug resistance, oncogenic signaling, and tumor-stress adaptation, providing a clinically relevant background for studying lung cancer biology.
HSPA6 is a stress-inducible HSP70 chaperone transcriptionally activated by HSF1 under heat shock, hypoxia, and oxidative stress. It binds and refolds misfolded proteins, maintaining proteostasis, and cooperates with co-chaperones HSP40 and BAG3, while targeting terminally misfolded substrates to the STUB1/CHIP ubiquitin ligase for degradation. This positions HSPA6 at the intersection of the heat shock response, unfolded protein response, and MAPK signaling, forming an HSF1-HSPA6-BAG3-STUB1 axis that governs cellular stress adaptation.
In NCI-H1975 cells, HSPA6 knockout disrupts a key stress-protective node, potentially exacerbating proteotoxic stress and shifting the balance toward apoptosis. Given the high basal stress in oncogene-driven NSCLC, loss of HSPA6 may impair management of misfolded proteins, leading to aggregation and altered viability. This model aids in deciphering how stress-inducible chaperones influence drug tolerance and survival in EGFR-mutant lung cancer.
This HSPA6 knockout polyclonal population is well-suited for a range of experimental applications. Researchers can evaluate protein aggregation using biochemical fractionation or fluorescence microscopy, assess cell viability under heat shock or chemotherapeutic stress via MTT/resazurin assays, and quantify apoptotic markers by flow cytometry. The model facilitates investigation of HSPA6-dependent modulation of the HSF1-BAG3-STUB1 pathway and its impact on MAPK signaling in TKI-resistant NSCLC. Additionally, it enables screening of small molecules targeting the chaperone network or validation of stress-response regulators. For technical inquiries, contact Ascent Research.
